Clinical Trial Update: Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cyclophosphamide therapy for refractory antibody-mediated rejection in kidney transplant recipients. The study has been termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: University of Manitoba | Conditions: Antibody Mediated Rejection | Phase 2 | Status: TERMINATED